GlassScriptPhysician profile
Thomas A Bosma
NPI 1255434544
$6,596.01
in general payments reported to CMS, 2019-2025
44 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,333 · 2022: $1,432 · 2023: $986 · 2024: $1,361 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,589 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,588.50 |
| Education | $242.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,132.96 | 2021-2025 | |
| Astellas Pharma US INC | $538.41 | 2021-2025 | Myrbetriq, Padcev, Xtandi |
| Janssen Biotech, INC. | $444.92 | 2022-2025 | Erleada, Balversa, Akeega |
| Coloplast Corp | $420.15 | 2021-2024 | Speedicath |
| Pfizer INC. | $338.09 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $335.14 | 2023-2025 | Orgovyx, Gemtesa |
| Progenics Pharmaceuticals, INC. | $279.96 | 2022-2025 | Pylarify |
| Myovant Sciences INC. | $228.92 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $225.77 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $218.31 | 2021-2025 | Oxlumo |
| Blue Earth Diagnostics | $188.39 | 2021-2022 | |
| Antares Pharma, INC. | $178.29 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Urogen Pharma, INC. | $169.14 | 2021-2025 | Jelmyto |
| Endo Pharmaceuticals INC. | $159.36 | 2021-2023 | Xiaflex, Aveed |
| Abc Home Medical Supply, INC. | $137.60 | 2022-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $135.31 | 2022-2025 | |
| Endo USA, INC. | $119.02 | 2024-2025 | Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $107.89 | 2021-2022 | |
| Procept Biorobotics Corporation | $101.10 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $85.68 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $79.02 | 2024-2025 | Adstiladrin |
| Axonics, INC. | $76.35 | 2022 | |
| Teleflex LLC | $75.72 | 2021-2025 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $75.00 | 2021 | |
| Smith+Nephew, INC. | $70.64 | 2022-2024 | Stravix |
| Tolmar Pharmaceuticals, INC. | $66.71 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $66.22 | 2022-2025 | Lynparza |
| Hollister Incorporated | $64.34 | 2023-2024 | Vapro, Vapro Pocket, Vapro Plus Pocket |
| Accord Healthcare, INC. | $57.63 | 2024-2025 | |
| Laborie Medical Technologies Corp. | $50.94 | 2023 | |
| Urovant Sciences INC | $48.32 | 2022 | |
| Merck Sharp & Dohme LLC | $42.21 | 2021-2022 | |
| Medtronic, INC. | $34.23 | 2024 | Ligasure |
| Sagent Pharmaceuticals | $30.29 | 2025 | Glydo |
| Ambu INC. | $28.99 | 2021 | |
| Becton, Dickinson and Company | $26.09 | 2024 | Bard Urinary Drainage Bag |
| C. R. Bard, INC. & Subsidiaries | $24.97 | 2024 | Bard Urinary Drainage Bag |
| Immunitybio, INC. | $24.14 | 2024 | |
| Dendreon Pharmaceuticals LLC | $22.44 | 2025 | Provenge |
| Olympus America INC. | $21.17 | 2023 | Itind System |
| Verity Pharmaceuticals INC. | $18.02 | 2025 | Tlando |
| Photocure INC | $17.40 | 2024 | Cysview |
| Conmed Corporation | $17.18 | 2024 | Conmed Specimen Retrieval |
| Halozyme INC | $13.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bosma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.